Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PN-4580
- Development stage
- Preclinical
- Lead developer
- Protagonist Therapeutics
- Modality
- Peptides
- Administration
- Oral, Subcutaneous
01
Overview
PN-4580 (also referred to as PN-458) is an investigational, wholly owned dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist peptide being developed by Protagonist Therapeutics for the treatment of obesity. Discovered using Protagonist's proprietary peptide technology platform, PN-4580 is designed to mimic the action of endogenous incretin hormones to promote satiety, delay gastric emptying, and improve glycemic control. The candidate is currently undergoing IND-enabling studies with optionality for both oral (PN-458o) and subcutaneous (PN-458sc) administration. Phase 1 clinical trials are anticipated to initiate in the second half of 2027.
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on PN-4580.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PN-4580.